Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

HIV resistance to reverse transcriptase inhibitors.

De Clercq E.

Biochem Pharmacol. 1994 Jan 20;47(2):155-69. Review. No abstract available.

PMID:
7508227
2.

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

Balzarini J, Karlsson A, Pérez-Pérez MJ, Camarasa MJ, De Clercq E.

Virology. 1993 Oct;196(2):576-85.

PMID:
7690501
3.

Specific HIV-1 reverse transcriptase inhibitors.

Debyser Z, Pauwels R, Andries K, De Clercq E.

J Enzyme Inhib. 1992;6(1):47-53. Review. No abstract available.

PMID:
1285302
4.

The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.

Emini EA, Byrnes VW, Condra JH, Schleif WA, Sardana VV.

Arch Virol Suppl. 1994;9:11-7. Review.

PMID:
7518271
5.
6.

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.

Buckheit RW Jr, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan BC, Chu SH, Bader JP.

Virology. 1995 Jun 20;210(1):186-93.

7.

Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors.

Alam M, Bechtold CM, Patick AK, Skoog MT, Gant TG, Colonno RJ, Meyers AI, Li H, Trimble J, Lin PF.

Antiviral Res. 1993 Oct;22(2-3):131-41.

PMID:
7506510
8.

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.

Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, Stevenson M, Tarpley WG.

Proc Natl Acad Sci U S A. 1993 May 15;90(10):4713-7.

9.

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Spence RA, Kati WM, Anderson KS, Johnson KA.

Science. 1995 Feb 17;267(5200):988-93.

PMID:
7532321
11.

Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.

Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ, Pauletti D, Shih CK, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J, Grob PM.

J Med Chem. 1998 Jul 30;41(16):2960-71.

PMID:
9685235
13.

Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors.

Condra JH, Emini EA, Gotlib L, Graham DJ, Schlabach AJ, Wolfgang JA, Colonno RJ, Sardana VV.

Antimicrob Agents Chemother. 1992 Jul;36(7):1441-6.

14.

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.

Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G.

Virology. 1994 May 1;200(2):696-701.

PMID:
7513921
15.
16.

A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.

Merluzzi VJ, Rosenthal AS.

Adv Exp Med Biol. 1992;312:89-94. Review. No abstract available.

PMID:
1381140
17.

TIBO derivatives: a new class of highly potent and specific inhibitors of HIV-1 replication.

Pauwels R, Andries K, Debyser Z, Kukla M, Schols D, Desmyter J, De Clercq E, Janssen PA.

Biochem Soc Trans. 1992 May;20(2):509-12. Review. No abstract available.

PMID:
1383063
19.

[Highly specific inhibitors of human immunodeficiency virus type I that are particularly targeted at the reverse transcriptase].

de Clercq E, Snoeck R.

Pathol Biol (Paris). 1993 Mar;41(3):230-6. Review. French. No abstract available.

PMID:
7687340
Items per page

Supplemental Content

Write to the Help Desk